-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on Lumexa Imaging Hldgs, Lowers Price Target to $9

Benzinga·05/20/2026 13:55:18
Listen to the news
Barclays analyst Andrew Mok maintains Lumexa Imaging Hldgs (NASDAQ:LMRI) with a Overweight and lowers the price target from $15 to $9.